Oncotelic Therapeutics: Phase 1b Trial Advances, Deciparticle Platform Validated
Oncotelic Therapeutics has completed the initial safety cohort of its Phase 1b SP-03-B101 trial, with a recommendation for dose escalation and European expansion. The company's Deciparticle™ platform also received peer-reviewed validation.
San Diego, California – July 7, 2026 – Oncotelic Therapeutics (OTCQB: OTLC) announced on Friday the successful completion of the initial safety cohort for its Phase 1b SP-03-B101 clinical trial. An independent safety review committee has recommended dose escalation and expansion into Europe.
The advancement of the clinical program occurs concurrently with the peer-reviewed validation of the company's proprietary Deciparticle™ nanomedicine platform, a key technology for its 45% owned subsidiary, Sapu Nano (US) LLC. This validation further supports the ongoing development of Sapu003.
Earlier in June, Oncotelic also announced a peer-reviewed publication validating the Deciparticle™ platform's potential for drug development. The study highlighted a novel intravenous formulation of everolimus and demonstrated the platform's broad applicability for hydrophobic therapeutics.
Additionally, Oncotelic launched an artificial intelligence (AI) powered Good Manufacturing Practices (GMP) manufacturing services platform in June. The company has also advanced its AI-powered GMP manufacturing services platform, in collaboration with TechForce Robotics, Inc., to commercialize AI and robotics manufacturing services. The company's PDAOAI™ capability was also showcased at the Qdrant Vector Space Day 2026 event.